Axonal damage in multiple sclerosis: a complex issue in a complex disease

Multiple sclerosis is no longer considered to simply be an autoimmune demyelinating disease. Axonal destruction is another central pathological feature and a contributor to the accumulating disability of disease progression. The mechanism underlying axonal pathology has not been fully clarified but does not appear to be a simple one. The relationship between axonal damage and other components of the pathological features such as demyelination, inflammation and remyelination are under intense investigation. Experimental data suggest that therapeutic interventions such as the induction of rapid remyelination may lead to the protection of axons. In addition to immunomodulation, future strategies for neuroprotection may be of great importance.

[1]  Kenneth J. Smith,et al.  Electrically active axons degenerate when exposed to nitric oxide , 2001, Annals of neurology.

[2]  Hans Lassmann,et al.  Clonal Expansions of Cd8+ T Cells Dominate the T Cell Infiltrate in Active Multiple Sclerosis Lesions as Shown by Micromanipulation and Single Cell Polymerase Chain Reaction , 2000, The Journal of experimental medicine.

[3]  F. Barkhof,et al.  Longitudinal brain volume measurement in multiple sclerosis: rate of brain atrophy is independent of the disease subtype. , 2002, Archives of neurology.

[4]  A. Thompson,et al.  Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. , 2003, Brain : a journal of neurology.

[5]  G Cutter,et al.  Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients , 2000 .

[6]  Pl Lantos,et al.  Greenfield's Neuropathology , 1985 .

[7]  T. Ben-Hur,et al.  Effects of proinflammatory cytokines on the growth, fate, and motility of multipotential neural precursor cells , 2003, Molecular and Cellular Neuroscience.

[8]  R. Hohlfeld.  Myelin failure in multiple sclerosis: Breaking the spell of Notch , 2002, Nature Medicine.

[9]  H. Wiśniewski,et al.  Axonal degeneration in demyelinating disorders , 1977, Journal of neurocytology.

[10]  C R Guttmann,et al.  A longitudinal study of callosal atrophy and interhemispheric dysfunction in relapsing-remitting multiple sclerosis. , 2001, Archives of neurology.

[11]  W. Mcdonald.  RACHELLE FISHMAN-MATTHEW MOORE LECTURE: The Pathological and Clinical Dynamics of Multiple Sclerosis , 1994, Journal of neuropathology and experimental neurology.

[12]  F. Condé,et al.  Early N-Acetylaspartate Depletion Is a Marker of Neuronal Dysfunction in Rats and Primates Chronically Treated with the Mitochondrial Toxin 3-Nitropropionic Acid , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[13]  A J Thompson,et al.  Brain atrophy in clinically early relapsing-remitting multiple sclerosis. , 2002, Brain : a journal of neurology.

[14]  Angelo L. Vescovi,et al.  Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis , 2003, Nature.

[15]  P M Matthews,et al.  Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. , 1998, Brain : a journal of neurology.

[16]  Fumio Nakamura,et al.  Identification of the Nogo inhibitor of axon regeneration as a Reticulon protein , 2000, Nature.

[17]  S. Waxman.  Demyelinating diseases--new pathological insights, new therapeutic targets. , 1998, The New England journal of medicine.

[18]  J. Correale,et al.  Oligoclonal bands and antibody responses in Multiple Sclerosis , 2002, Journal of Neurology.

[19]  S. Strittmatter,et al.  Targeting the Nogo Receptor to Treat Central Nervous System Injuries , 2003, Nature Reviews Drug Discovery.

[20]  D. Piani,et al.  Involvement of the cystine transport system xc- in the macrophage-induced glutamate-dependent cytotoxicity to neurons. , 1994, Journal of immunology.

[21]  T. Olsson,et al.  Increased Brain‐Derived Neurotrophic Factor Expression in White Blood Cells of Relapsing–Remitting Multiple Sclerosis Patients , 2003, Scandinavian journal of immunology.

[22]  T. Ben-Hur,et al.  Transplanted multipotential neural precursor cells migrate into the inflamed white matter in response to experimental autoimmune encephalomyelitis , 2003, Glia.

[23]  R. Rudick,et al.  Neurodegeneration in Multiple Sclerosis: Relationship to Neurological Disability , 1999 .

[24]  B. Trapp,et al.  Axon Loss in the Spinal Cord Determines Permanent Neurological Disability in an Animal Model of Multiple Sclerosis , 2002, Journal of neuropathology and experimental neurology.

[25]  A. Thompson,et al.  Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. , 1995, Brain : a journal of neurology.

[26]  W. Brück,et al.  Oligodendrocyte and axon pathology in clinically silent multiple sclerosis lesions , 1998, Multiple sclerosis.

[27]  H. Lassmann.  Brain damage when multiple sclerosis is diagnosed clinically , 2003, The Lancet.

[28]  T. J. Putnam.  STUDIES IN MULTIPLE SCLEROSIS: VII. SIMILARITIES BETWEEN SOME FORMS OF ENCEPHALOMYELITIS AND MULTIPLE SCLEROSIS , 1936 .

[29]  E. Silber,et al.  Patients with progressive multiple sclerosis have elevated antibodies to neurofilament subunit , 2002, Neurology.

[30]  M. Palkovits,et al.  Axonal changes in chronic demyelinated cervical spinal cord plaques. , 2000, Brain : a journal of neurology.

[31]  Ganter,et al.  Spinal cord axonal loss in multiple sclerosis: a post‐mortem study , 1999, Neuropathology and applied neurobiology.

[32]  P. Thibault,et al.  Oligodendrocyte‐myelin glycoprotein (OMgp) is an inhibitor of neurite outgrowth , 2002, Journal of neurochemistry.

[33]  Kenneth J. Smith,et al.  Blockers of sodium and calcium entry protect axons from nitric oxide‐mediated degeneration , 2003, Annals of neurology.

[34]  Saul A. Teukolsky,et al.  Black Holes , 1998 .

[35]  A. Scheibel,et al.  Degeneration and regeneration of the nervous system , 1960 .

[36]  H. Neumann,et al.  Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases , 2002, Trends in Neurosciences.

[37]  T. Owens,et al.  The immunology of multiple sclerosis and its animal model, experimental allergic encephalomyelitis. , 1995, Neurologic clinics.

[38]  M. Cynader,et al.  Dendritic and synaptic pathology in experimental autoimmune encephalomyelitis. , 2003, The American journal of pathology.

[39]  W. Brück,et al.  Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. , 2000, Brain : a journal of neurology.

[40]  N. Grigoriadis.  Interferon β treatment in relapsing–remitting multiple sclerosis. A review , 2002, Clinical Neurology and Neurosurgery.

[41]  Martin E. Schwab,et al.  Nogo-A is a myelin-associated neurite outgrowth inhibitor and an antigen for monoclonal antibody IN-1 , 2000, Nature.

[42]  M Rovaris,et al.  Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. , 2003, Brain : a journal of neurology.

[43]  Moses Rodriguez,et al.  Preservation of neurologic function during inflammatory demyelination correlates with axon sparing in a mouse model of multiple sclerosis , 2002, Neuroscience.

[44]  P. Matthews,et al.  Putting Magnetic Resonance Spectroscopy Studies in Context: Axonal Damage and Disability in Multiple Sclerosis , 1998, Seminars in neurology.

[45]  J. Garthwaite,et al.  Nitric oxide toxicity in CNS white matter: an in vitro study using rat optic nerve , 2002, Neuroscience.

[46]  V. Perry,et al.  Axonal damage in acute multiple sclerosis lesions. , 1997, Brain : a journal of neurology.

[47]  D. Pitt,et al.  Glutamate excitotoxicity in a model of multiple sclerosis , 2000, Nature Medicine.

[48]  H. Neumann,et al.  Transection of major histocompatibility complex class I-induced neurites by cytotoxic T lymphocytes. , 2001, The American journal of pathology.

[49]  B. Lewis,et al.  Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFN&bgr;-1b , 2002, Neurology.

[50]  T. Gennarelli,et al.  The spectrum of traumatic axonal injury , 1996, Neuropathology and applied neurobiology.

[51]  Wolfgang Brück,et al.  Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. , 2002, Brain : a journal of neurology.

[52]  M. Filbin,et al.  A novel role for myelin-associated glycoprotein as an inhibitor of axonal regeneration , 1994, Neuron.

[53]  D. Pham‐Dinh,et al.  Pathological and regulatory effects of anti-myelin antibodies in experimental allergic encephalomyelitis in mice , 2002, Journal of Neuroimmunology.

[54]  P M Matthews,et al.  In vivo evidence for axonal dysfunction remote from focal cerebral demyelination of the type seen in multiple sclerosis. , 1999, Brain : a journal of neurology.

[55]  P. Rieckmann,et al.  Anti‐inflammatory strategies to prevent axonal injury in multiple sclerosis , 2002, Current opinion in neurology.

[56]  V. Perry,et al.  Axon pathology in neurological disease: a neglected therapeutic target , 2002, Trends in Neurosciences.

[57]  M. Horsfield,et al.  A 6‐year clinical and MRI follow‐up study of patients with relapsing–remitting multiple sclerosis treated with Interferon‐beta , 2002, European journal of neurology.

[58]  Moses Rodriguez.  A function of myelin is to protect axons from subsequent injury: implications for deficits in multiple sclerosis. , 2003, Brain : a journal of neurology.

[59]  J. Zajicek,et al.  Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis ( CAMS study ) : multicentre randomised placebo-controlled trial , 2022 .

[60]  G. Barker,et al.  Correlation of magnetic resonance imaging parameters with clinical disability in multiple sclerosis: a preliminary study , 1999, Journal of Neurology.

[61]  A. Cross,et al.  Axonal dystrophy as a consequence of long-term demyelination. , 1989, Laboratory investigation; a journal of technical methods and pathology.

[62]  Yves-Alain Barde,et al.  Neurotrophin-3 enhances sprouting of corticospinal tract during development and after adult spinal cord lesion , 1994, Nature.

[63]  W. Mcdonald,et al.  The pathological evolution of multiple sclerosis , 1992, Neuropathology and applied neurobiology.

[64]  L. Leocani,et al.  Neurophysiological investigations in multiple sclerosis. , 2000, Current opinion in neurology.

[65]  S G Waxman,et al.  Ionic mechanisms of anoxic injury in mammalian CNS white matter: role of Na+ channels and Na(+)-Ca2+ exchanger , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[66]  P. Matthews,et al.  Chemical pathology of acute demyelinating lesions and its correlation with disability , 1995, Annals of neurology.

[67]  B. Trapp,et al.  Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions , 2001, Annals of neurology.

[68]  J. Minckler.  Pathology of the nervous system , 1968 .

[69]  B. Trapp,et al.  Subpial Demyelination in the Cerebral Cortex of Multiple Sclerosis Patients , 2003, Journal of neuropathology and experimental neurology.

[70]  J. Cosgrove,et al.  Studies in multiple sclerosis , 1965, Neurology.

[71]  M Filippi,et al.  Long-term changes of magnetization transfer-derived measures from patients with relapsing-remitting and secondary progressive multiple sclerosis. , 1999, AJNR. American journal of neuroradiology.

[72]  Caterina Mainero,et al.  Brain atrophy in relapsing-remitting multiple sclerosis: relationship with ‘black holes’, disease duration and clinical disability , 2000, Journal of the Neurological Sciences.

[73]  R. Prinjha,et al.  Neurobiology: Inhibitor of neurite outgrowth in humans , 2000, Nature.

[74]  A. Thompson,et al.  The therapeutic potential of cannabis , 2003, The Lancet Neurology.

[75]  F. Gage,et al.  Cellular Delivery of Neurotrophin-3 Promotes Corticospinal Axonal Growth and Partial Functional Recovery after Spinal Cord Injury , 1997, The Journal of Neuroscience.

[76]  D S Goodin,et al.  Disease modifying therapies in multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines , 2002, Neurology.

[77]  J. Goverman,et al.  A Pathogenic Role for Myelin-Specific Cd8+ T Cells in a Model for Multiple Sclerosis , 2001, The Journal of experimental medicine.

[78]  C. Brosnan,et al.  Multiple sclerosis: Re-expression of a developmental pathway that restricts oligodendrocyte maturation , 2002, Nature Medicine.

[79]  C. Pozzilli,et al.  MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a , 2002, Multiple sclerosis.

[80]  Hans Lassmann,et al.  Activated Human T Cells, B Cells, and Monocytes Produce Brain-derived Neurotrophic Factor In Vitro and in Inflammatory Brain Lesions: A Neuroprotective Role of Inflammation? , 1999, The Journal of experimental medicine.

[81]  S. Dhib-jalbut,et al.  Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor , 2003, Journal of the Neurological Sciences.

[82]  R. Rudick,et al.  Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. , 2002, The New England journal of medicine.

[83]  C H Polman,et al.  Cerebral volume changes in multiple sclerosis patients treated with high-dose intravenous methylprednisolone , 2002, Multiple sclerosis.

[84]  Zografos Caramanos,et al.  Axonal metabolic recovery in multiple sclerosis patients treated with interferon β–1b , 2001, Journal of Neurology.

[85]  P. Matthews,et al.  Beta-Interferon treatment does not always slow the progression of axonal injury in multiple sclerosis , 2003, Journal of Neurology.

[86]  R. Rudick,et al.  Axonal transection in the lesions of multiple sclerosis. , 1998, The New England journal of medicine.

[87]  H. Lassmann,et al.  Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. , 2000, The American journal of pathology.

[88]  P. Matthews,et al.  Regional axonal loss in the corpus callosum correlates with cerebral white matter lesion volume and distribution in multiple sclerosis. , 2000, Brain : a journal of neurology.

[89]  Raine Cs.  Biology of disease. Analysis of autoimmune demyelination: its impact upon multiple sclerosis. , 1984 .

[90]  S. Ben-Shabat,et al.  An endogenous cannabinoid (2-AG) is neuroprotective after brain injury , 2001, Nature.

[91]  J. Borrell,et al.  Therapeutic Action of Cannabinoids in a Murine Model of Multiple Sclerosis , 2003, The Journal of Neuroscience.

[92]  B. Trapp,et al.  Interferon-β inhibits progression of relapsing-remitting experimental autoimmune encephalomyelitis , 1996, Journal of Neuroimmunology.